Medical sterilization company Sterilis said yesterday it tapped former Nanosphere (NSDQ:NSPH) chief exec Michael McGarrity as its new CEO.
McGarrity held the CEO position at Nanosphere from February 2013 to last June when he oversaw the company’s $76.9 million acquisition by Luminex (NSDQ:LMNX).
Prior to his time as head of Nanosphere, McGarrity held positions in sales, marketing and operations at Stryker (NYSE:SYK) where he led the company into markets including post-operative pain management, surgical fluid waste management and interventional pain management.
“Bob Winskowicz and the dedicated and talented team at Sterilis have developed a highly disruptive approach to treating infectious medical waste at the point-of-care. Sterilis’ compelling value proposition and broad customer base position the company to rapidly become a major player in the global RMW industry. I would like to thank Bob Winskowicz and the Board of Directors for the confidence they have placed in me to lead the next phase of the company’s growth. I am committed to building significant value for all of our stakeholders including customers, employees and shareholders,” McGarrity said in a press release.
Cathworks appoints former Boston Scientific prez Corbett as CEO
CathWorks said last week it appointed former Boston Scientific (NYSE:BSX) international prez James Corbett as its chief executive officer.
During his medtech career, Corbett has held positions at Home Diagnostics, ev3, Vertos Medical and Alphatec (NSDQ:ATEC) , the Israel-based company said.
“We are excited to have Jim join to lead the company in its efforts to globally commercialize the FFRangio technology,” founder and former CEO Guy Lavi said in a press release. Lavi will stay on and hold the position of president, CathWorks said.
“Having Jim join CathWorks at this point, demonstrates an important transition of CathWorks to the next stage of development. Jim brings the experience and achievement necessary to develop the global organization that can execute on the significant opportunity created by the FFRangio technology,” board chair Scott Ward said in a press release.
LinkSpine lifts Farrell to CEO
LinkSpine said late last week it promoted president Dennis Farrell both CEO and president of the company.
Farrell joined LinkSpine in 2011 and has served as prez since 2015, previously leading the company’s sales, marketing and product development initiatives.
“We are very pleased to announce the promotion of Dennis Farrell to chief executive officer of LinkSpine, Inc. Dennis started with the company nearly six years ago and has advanced through progressive development of our MidlineChoice Platform as a member of our executive management team. With his experience, expertise and knowledge as well as his communication skills and surgeon relationships, he has provided an invaluable resource to the company. As CEO, Dennis will be responsible for the oversight of day to day corporate operations, human resource management as well as quality assurance and all reportingWe are excited about his new role at the company and look very much forward to a bright future of LinkSpine under his leadership,” Link company chair Helmut Link said in a prepared statement.
“I am excited about and grateful for the opportunity to continue working with LinkSpine’s exceptional team. We remain committed to developing innovative solutions that are designed for placement with minimal fluoro and shorter learning curves than tubular MIS techniques, offering the potential for reduced surgical morbidity. It is particularly rewarding to be able to offer, through LinkSpine’s MidlineChoice, a platform designed specifically to provide surgeons enhanced flexibility. With our technology, the surgeon community can intra-operatively customize the fusion construct based upon patient anatomy, pathology, and preference. Novel, cross-linked two screw constructs are available in addition to cortical and pedicle screws, ensuring the desired implant options are available on game day even if the game plan changes according to intra-operative discovery,” Farrell said in a press release.
AdvaMed Accell taps Baylis’ Shah for board
Baylis Medical said last week that its prez & co-founder Kris Shah has been named to AdvaMed’s Accel board of directors.
AdvaMed Accel is the industry groups division which looks to address the “unique needs and challenges of smaller medical device and diagnostics manufacturers,” according to a press release.
“I am honoured to be appointed to the AdvaMed Accel Board and look forward to working with this distinguished group of professionals to advance medical innovations that result in healthier lives and healthier economics around the world. I am particularly pleased to be joining an association that shares Baylis Medical’s adherence to the highest ethical standards and commitment for improving patients’ lives,” Shah said in a prepared statement.
“We are pleased to have Kris joining our Accel Board of Director. His business, engineering and commercialization experience bring a wealth of expertise to the Accel Board. In addition, his insight into international markets will be invaluable as we address the unique overseas challenges facing smaller medtech companies,” AdvaMed Accel exec director Ashley Wittorf said in a prepared release.
Second Sight Medical appoints Vandeputte as EMEA & Asia Pacific VP, GM
Second Sight Medical (NSDQ:EYES) said late last month it appointed Frank Vandeputte as its new EMEA and Asia Pacific vp & GM.
Prior to joining Secong Sight, Vandeputte held positions at TriVascular, Aptus Endosystems, EBR Systems, Oxford Immuniotech, Sorin Group and Guidant.
“Frank joins us with more than 30 years of sales and marketing experience in medical devices. His leadership and commercialization experience, coupled with our strong team in Europe, will position us for continued success outside of the U.S. and Canada. I’m also very pleased that Greg has assumed a new position leading our clinical affairs team. His first priority is the initiation of the Orion feasibility trial followed by the planning and execution of a pivotal trial. Orion is an exciting technology that can potentially restore useful vision to millions of patients who today have no option,” prez & CEO Will McGuire said in a press release.
The company also announced it tapped Dr. Gregoire Cosendai as clinical affairs VP, promoted from VP of European Operations.